1. Home
  2. LSBPW vs EPRT Comparison

LSBPW vs EPRT Comparison

Compare LSBPW & EPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LSBPW
  • EPRT
  • Stock Information
  • Founded
  • LSBPW N/A
  • EPRT 2016
  • Country
  • LSBPW China
  • EPRT United States
  • Employees
  • LSBPW 758
  • EPRT N/A
  • Industry
  • LSBPW Biotechnology: Pharmaceutical Preparations
  • EPRT Real Estate Investment Trusts
  • Sector
  • LSBPW Health Care
  • EPRT Real Estate
  • Exchange
  • LSBPW Nasdaq
  • EPRT Nasdaq
  • Market Cap
  • LSBPW N/A
  • EPRT N/A
  • IPO Year
  • LSBPW N/A
  • EPRT 2018
  • Fundamental
  • Price
  • LSBPW $0.05
  • EPRT $31.53
  • Analyst Decision
  • LSBPW
  • EPRT Strong Buy
  • Analyst Count
  • LSBPW 0
  • EPRT 16
  • Target Price
  • LSBPW N/A
  • EPRT $33.92
  • AVG Volume (30 Days)
  • LSBPW N/A
  • EPRT 1.3M
  • Earning Date
  • LSBPW N/A
  • EPRT 02-12-2025
  • Dividend Yield
  • LSBPW N/A
  • EPRT 3.68%
  • EPS Growth
  • LSBPW N/A
  • EPRT N/A
  • EPS
  • LSBPW N/A
  • EPRT 1.15
  • Revenue
  • LSBPW N/A
  • EPRT $428,535,000.00
  • Revenue This Year
  • LSBPW N/A
  • EPRT N/A
  • Revenue Next Year
  • LSBPW N/A
  • EPRT $18.79
  • P/E Ratio
  • LSBPW N/A
  • EPRT $27.44
  • Revenue Growth
  • LSBPW N/A
  • EPRT 27.83
  • 52 Week Low
  • LSBPW N/A
  • EPRT $23.58
  • 52 Week High
  • LSBPW N/A
  • EPRT $34.88
  • Technical
  • Relative Strength Index (RSI)
  • LSBPW N/A
  • EPRT 38.76
  • Support Level
  • LSBPW N/A
  • EPRT $32.54
  • Resistance Level
  • LSBPW N/A
  • EPRT $33.05
  • Average True Range (ATR)
  • LSBPW 0.00
  • EPRT 0.69
  • MACD
  • LSBPW 0.00
  • EPRT -0.22
  • Stochastic Oscillator
  • LSBPW 0.00
  • EPRT 30.10

About LSBPW LakeShore Biopharma Co. Ltd

LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.

Share on Social Networks: